NewsSignificant Gender Disparities in COVID-19 Clinical Trial LeadershipQueen Mary University of London | March 8, 2021 Less than a third of COVID-19 trials are led by women, half the proportion observed in non-COVID-19 trials
NewsImmunotherapy Drug Delays Onset of Type 1 Diabetes in At-Risk GroupYale University | March 3, 2021 If approved for use, it would be the first drug to delay or prevent Type 1 diabetes
NewsReal-World Effectiveness of COVID-19 VaccineClalit Research Institute | February 25, 2021 First peer-reviewed real-world study of COVID-19 vaccine examined 600,000 vaccinated individuals
NewsCombined Neoadjuvant Immunotherapy Improves NSCLC OutcomesUniversity of Texas MD Anderson Cancer Center | February 18, 2021 This is the first randomized study to report on the role of combination checkpoint inhibitors for early stage NSCLC
NewsNew Drug Leads to 30% Reduced Risk of Death for Bladder Cancer PatientsQueen Mary University of London | February 12, 2021 A new type of drug that targets chemotherapy directly to cancer cells significantly increased patient survival
NewsPhase 3 Trials Show Oxford COVID-19 Vaccine Is Safe and Protects against DiseaseThe Lancet | December 8, 2020 The first clinical efficacy results of the vaccine are based on a pre-specified pooled analysis of phase 3 trials in the UK and Brazil
NewsLatest Data Shows Oxford's COVID-19 Vaccine Is 70.4 Percent EffectiveMiriam Bergeret, MSc | November 24, 2020 The results are based on two dosing schedules, one of which is 90 percent effective
NewsPhase 2 Trial of Oxford COVID-19 Vaccine in Older Adults Finds It Is SafeThe Lancet | November 20, 2020 Robust antibody and T-cell response seen in older adults is encouraging
NewsEarly Analysis Finds Moderna's COVID-19 Vaccine Is 94.5 Percent EffectiveMiriam Bergeret, MSc | November 19, 2020 The vaccine trial reports 95 confirmed cases of COVID-19 with only 5 in the vaccinated group—a statistically significant result
NewsHydroxychloroquine Does Not Help Patients Hospitalized with COVID-19Vanderbilt University Medical Center | November 13, 2020 Compared to inactive placebo, hydroxychloroquine did not significantly improve outcomes of hospitalized patients